郭思治: 國投等背書心瑋醫療(06609.HK) 領跑神經介入賽道
香港股票分析師協會副主席郭思治稱,中國神經介入頭部企業之一的心瑋醫療(06609.HK)招股進去第三天。作為創新型神經介入醫療器械公司,隨著未來國內醫療體系完善和人們可負擔能力提升而帶來的產品需求增長,預計公司可繼續穩居該細分市場龍頭,心瑋醫療定可成為醫療器械板塊的必選股之一。
公司的獨角獸潛力獲得眾多投資者認可,投資者包括:淡馬錫、加拿大養老基金、醫療保健領域知名資產管理公司LYFE和國投集團旗下專業引導及產業基金管理機構國投創合基金等。
心瑋醫療憑藉在研發、生產及商業化方面的卓越能力,致力通過商業化在研產品,降低中國乃至全球的腦卒中死亡率並改善預後。公司產品組合包括神經介入及心臟醫療器械,擁有四款商業化產品及19 款在研產品,覆蓋了神經介入領域的所有主要腦卒中亞型及手術路徑,以及心臟醫療器械領域缺血性腦卒中預防等。
公司的所有商業化產品及在研產品,從設計到後續的產品註冊及商業化的整個過程均屬內部研發。公司核心產品是CaptorTM取栓器械(Captor)及左心耳(LAA)封堵器。其中,Captor針對急性缺血性腦卒中,且已在中國實現商業化,而封堵器是為心房顫動而研發,正待NMPA的註冊審查。
(筆者為證監會持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.